Last edition
News about
The collaboration between Boehringer Ingelheim and BioNTech will evaluate a dual immuno-oncology approach in extensive-stage small cell lung cancer, aiming to improve outcomes in a disease with limited treatment options.
Lynk Pharmaceuticals Secures NMPA NDA Acceptance for Zemprocitinib
Lynk Pharmaceuticals announces NMPA acceptance of Zemprocitinib NDA, backed by positive results from a phase-III randomised, double-blind, placebo-controlled clinical trial in China.
Pendulum Therapeutics Expands Microbiome Research in Women's Health and Dermatology
Pendulum Therapeutics expands its long-standing clinical collaboration with Mayo Clinic to advance microbiome-based interventions in women’s health and dermatology, building on a partnership established in 2013.
Novo Nordisk's Wegovy Gets EU Approval for 48-Hour Controlled-Temperature Delivery
Novo Nordisk’s Wegovy becomes the first GLP-1 weight-loss treatment approved in the EU for 48-hour controlled-temperature delivery, improving storage flexibility and patient access.
AI-Driven Drug Discovery Workshop Held at CSIR-HRDC Ghaziabad
A three-day AI-driven drug discovery workshop at CSIR-HRDC Ghaziabad equipped CSIR scientists and technical officers with advanced tools, techniques, and applications in modern pharmaceutical research.
Croma-Pharma Acquires Synocrom, Re-Enters Orthopaedics
Croma-Pharma acquires Synocrom to re-enter orthopaedics, expanding its portfolio with a hyaluronic acid treatment for knee osteoarthritis launching in the EU and Switzerland in May 2026.
Emalex Secures US Patent for Ecopipam ODT
Emalex secures a US composition-of-matter patent for its orally disintegrating ecopipam formulation, advancing drug development and expanding patient access.
DualityBio Secures China NMPA BLA Acceptance for Trastuzumab Pamirtecan in HER2+ Breast Cancer
DualityBio announces China NMPA acceptance of its BLA for trastuzumab pamirtecan, targeting unresectable or metastatic HER2-positive breast cancer in adult patients.
Forte Biosciences Announces Pricing of USD 150 Million Public Offering
Forte Biosciences announces pricing of its USD 150 million public offering, with expected gross proceeds of USD 150 million before underwriting discounts, commissions, and offering expenses.
Centre Engages Domestic Firms to Stabilise Methanol Supply for Drug Industry
The Indian government is actively engaging domestic producers, including Assam Petro-Chemicals Limited and Gujarat Narmada Valley Fertilizers & Chemicals Limited, to secure a steady supply of methanol for the pharmaceutical sector amid ongoing disruptions in West Asia.
We use our own and third party cookies to produce statistical information and show you personalized advertising by analyzing your browsing, according to our COOKIES POLICY. If you continue visiting our Site, you accept its use.
More information: Privacy Policy